TrialCancer medicine2022

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Shinichi Makita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.